Clinical trials: Severe Community-Acquired Pneumonia
Influenza
Adaptive RCT of Corticosteroids for Severe Influenza Pneumonia in Adults
Severe community-acquired pneumonia caused by influenza virus (hereafter referred to as severe influenza pneumonia) is a major etiology of community-acquired pneumonia leading to acute respiratory failure and ICU admission.
- Trial name
- CAPSTONE-IFV (NCT07351500)
- Testing
- Saline (0.9%, sterile, for infusion), low dose Methylprednisolone, Moderate dose Methylprednisolone
- Volunteers
- 496 people
- Sponsor
- Qingyuan Zhan
Pneumonia, Pneumococcal Infections
Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae
The objectives of this study are to assess the safety, tolerability, clinical and microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by Streptococcus pneumoniae after the intravenous…
- Trial name
- NCT02583373
- Testing
- CAL02 Low-dose, CAL02 High-dose
- Where
- 10 sites in Belgium, France
- Volunteers
- 19 people
- Sponsor
- Combioxin SA
Community-Acquired Infections
Cohort Study on the Treatment of Severe Pneumonia with Traditional Chinese Medicine
This is a multicenter, prospective cohort study, with syndrome differentiation and treatment of traditional Chinese medicine as the exposure factor.
- Trial name
- NCT06613659
- Testing
- traditional Chinese medicine (TCM), non traditional Chinese medicine (non-TCM)
- Where
- China
- Volunteers
- 1,016 people
- Sponsor
- Henan University of Traditional Chinese Medicine
Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS)
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
This is a Phase 3, randomized, blinded, and placebo-controlled clinical trial investigating a new combination treatment for critically ill adults who have severe community-acquired pneumonia, especially if they also have sepsis…
- Conditions
- Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia
- Trial name
- NCT07492875
- Testing
- Nogapendekin alfa inbakicept (NAI), agenT-797
- Sponsor
- ImmunityBio, Inc.
Pneumonia
Does Azithromycin Cause QT Prolongation in Hospitalized Patients With Severe Community Acquired Pneumonia?
The macrolide group of antibiotics can cause QT prolongation, and endanger the patient with life threatening arrythmias. QT prolongation caused by Azythromycin, a relatively new macrolide, is extremely rare, and was not reported…
- Trial name
- NCT01553734
- Where
- Israel
- Volunteers
- 148 people
- Sponsor
- HaEmek Medical Center, Israel
Covid19
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
The objectives of the trial are to evaluate the efficacy and safety of trimodulin as add-on therapy to standard of care (SoC) compared to placebo treatment in adult hospitalized subjects with severe COVID-19.
- Trial name
- ESsCOVID (NCT04576728)
- Testing
- Trimodulin
- Where
- 17 sites in Brazil, France and 2 more
- Volunteers
- 166 people
- Sponsor
- Biotest
Severe Communtity-Acquired Pneumonia
Study on Costs and Safety of Early Conversion From Intravenous to Oral Antibiotic Treatment in Patients With Severe Community-Acquired Pneumonia
Patients with severe community-acquired pneumonia are included Half of the patients are treated with a 3 day course of intravenous antibiotics, followed, when clinical stable, by a course of oral antibiotics.
- Trial name
- NCT00273676
- Testing
- Conversion to oral antibiotic treatment after 3 days of intravenous antibiotic treatment
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- UMC Utrecht
Pneumonia, Bacterial
Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae.
- Trial name
- NCT00538694
- Testing
- daptomycin
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Community-acquired Pneumonia, Severe Pneumonia
Fulminant Severe CAP - an Observational Study
Severe community-acquired pneumonia (CAP) represents a major cause of hospital mortality. Among severe CAP cases, some exhibit a rapidly progressive evolution, leading to severe ARDS/acute respiratory failure and septic shock…
- Conditions
- Community-acquired Pneumonia, Severe Pneumonia, ARDS, Human, Sepsis
- Trial name
- FULMISCAP (NCT06516601)
- Testing
- no intervention
- Where
- 2 sites in Italy
- Volunteers
- 1,460 people
- Sponsor
- University of Trieste
COVID-19, Undefined
A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia
The purpose of this study is to determine if an investigational drug, AT-100, is safe and tolerated by adults who have severe corona virus disease 2019 (COVID-19) or respiratory failure secondary to severe community acquired…
- Trial name
- NCT04659122
- Testing
- AT-100
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Airway Therapeutics, Inc.
Severe Pneumonia, Community-acquired Pneumonia
Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients
Ambroxol is a mucolytic containing an active N-desmethyl metabolite of bromhexine. It is approved by both the U.S. FDA and EMA to be marketed under several formulations including oral, nasal, oro-mucosal, rectal and intravenous…
- Conditions
- Severe Pneumonia, Community-acquired Pneumonia, Hospital-acquired Pneumonia, Critical Illness
- Trial name
- NCT05663905
- Testing
- Ambroxol Hydrochloride, Standard Therapy
- Where
- Malaysia
- Volunteers
- 32 people
- Sponsor
- National University of Malaysia
Community-Acquired Pneumonia (CAP)
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens.
- Trial name
- NCT00035347
- Testing
- IV azithromycin, ceftriaxone, oral azithromycin
- Where
- 37 sites in United States, Canada and 3 more
- Volunteers
- 219 people
- Sponsor
- Pfizer
Pneumonia, Bacterial
Sphingosine-1-phosphate and Pneumonia
Pneumonia is a major infectious cause of death worldwide and imposes a considerable burden on healthcare resources. Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid and involved in many physiological processes including…
- Trial name
- SOPN (NCT04007328)
- Testing
- Methylprednisolone Sodium Succinate
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- Taipei Medical University WanFang Hospital
Pneumonia
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of…
- Trial name
- NCT01561794
- Testing
- Ciprofloxacin (Cipro, BAYQ3939)
- Where
- 20 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Bayer
Severe Community-acquired Pneumonia
Amoxicillin/Clavulanic Acid Susceptibility in Acute Community-acquired Pneumonia Requiring Intensive Care Management
Severe community-acquired pneumonia (CAP) and community-acquired aspiration pneumonia (CAAP) are common reasons for adult emergency department visits and subsequent admission to the intensive care unit (ICU).
- Trial name
- CAP-ICU (NCT07322549)
- Testing
- Susceptibility to AMC, Susceptibilty to 3GC
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer